Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease (AD) is a leading neurodegenerative disorder in the elderly.
• Amyloid-beta (Aβ) accumulation is a key factor in AD pathogenesis.
• Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates Aβ production.

Purpose of the Study:

• To review the consequences of BACE1 inhibition on synaptic plasticity.
• To discuss the potential clinical implications of BACE1 inhibitor-induced side effects.

Main Methods:

• Review of existing literature on BACE1 inhibitors and synaptic function.
• Analysis of studies investigating adverse effects of BACE1 inhibition in animal models.

Main Results:

• BACE1 inhibitors are a promising therapeutic strategy for AD by reducing Aβ.
• High-dose BACE1 inhibition in mice impairs synaptic plasticity.
• These synaptic deficits may obscure the therapeutic efficacy of Aβ reduction.

Conclusions:

• BACE1 inhibition presents a potential AD treatment, but synaptic side effects require careful consideration.
• Understanding and mitigating BACE1-mediated synaptic deficits are crucial for successful clinical translation.